Sang-Woo Park
Vorstandsvorsitzender bei NKMAX CO., LTD.
Vermögen: 794 962 $ am 30.04.2024
Profil
Sang-Woo Park is the founder of NKMAX Co., Ltd.
(founded in 2002) and NKGen Operating Biotech, Inc. (founded in 2002).
He is also the founder of NKGen Biotech, Inc. Mr. Park's current jobs include Chief Executive Officer & Director at NKMAX Co., Ltd.
(South Korea), Chief Executive Officer at ATGen Canada, Inc., Chief Executive Officer at ATGen America, Inc., Chief Executive Officer at Atgen H&D, Chief Executive Officer at coAsia Biotech Corp., Chief Executive Officer at Nkmax H&D Co. Ltd., Chief Executive Officer at Atgen Japan, and Chief Executive Officer at Nkmax Japan, Inc. Mr. Park's former job was Chief Executive Officer & Director at J way Co., Ltd.
He completed his undergraduate degree at Korea University.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
1,74% | 13.12.2023 | 397 378 ( 1,74% ) | 786 808 $ | 30.04.2024 |
NKMAX CO., LTD.
0,01% | 26.01.2024 | 5 418 ( 0,01% ) | 8 154 $ | 31.03.2024 |
Aktive Positionen von Sang-Woo Park
| Unternehmen | Position | Beginn |
|---|---|---|
| NKMAX CO., LTD. | Vorstandsvorsitzender | 14.01.2002 |
| ATGen America, Inc. | Vorstandsvorsitzender | 01.02.2014 |
| ATGen Canada, Inc. | Vorstandsvorsitzender | 01.09.2013 |
Atgen H&D
 Atgen H&D Pharmaceuticals: OtherHealth Technology Atgen H&D develops protein products. Sang-Woo Park has been the CEO of the South Korean company since 2016. | Vorstandsvorsitzender | 01.01.2016 |
NKMAX Co., Ltd.
 NKMAX Co., Ltd. Pharmaceuticals: MajorHealth Technology NKMAX Co., Ltd. engages in the manufacture and sale of pharmaceutical products. It operates through the following business divisions: Immunity Cell Cure, Immunodiagnosis Kit, Health Functional Foods, and Bio Research. The company was founded on January 14, 2002 and is headquartered in Seongnam-si, South Korea. | Vorstandsvorsitzender | 01.01.2002 |
| Nkmax H&D Co. Ltd. | Vorstandsvorsitzender | 01.06.2016 |
coAsia Biotech Corp.
 coAsia Biotech Corp. BiotechnologyHealth Technology Part of NKMAX Co., Ltd. (South Korea), coAsia Biotech Corp. manufactures biological products. Sang-Woo Park has been the CEO of the Thai company since 2016. coAsia Biotech was acquired by NKMAX Co., Ltd. (South Korea) on February 28, 2018 for $0.10 million. | Vorstandsvorsitzender | 01.04.2016 |
| Atgen Japan | Vorstandsvorsitzender | 01.09.2017 |
NKGen Biotech, Inc.
 NKGen Biotech, Inc. BiotechnologyHealth Technology NKGen Biotech, Inc. is a biotechnology company which engages in harnessing the immune system through natural killer cell therapies. It develops a proprietary stabilizing peptide, monoclonal antibodies, and recombinant proteins for research use. The company was founded in 2002 and is headquartered in Santa Ana, CA. | Gründer | 01.01.2002 |
| ░░░░░ ░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Ehemalige bekannte Positionen von Sang-Woo Park
| Unternehmen | Position | Ende |
|---|---|---|
| ░ ░░░ ░░░░ ░░░░ | ░░░░░░░░░░░░░░░░░░░░░ | - |
Ausbildung von Sang-Woo Park
| Korea University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| J WAY CO., LTD. | Consumer Services |
| NKMAX CO., LTD. | Health Technology |
| Private Unternehmen | 9 |
|---|---|
| ATGen Canada, Inc. | |
| ATGen America, Inc. | |
Atgen H&D
Atgen H&D Pharmaceuticals: OtherHealth Technology Atgen H&D develops protein products. Sang-Woo Park has been the CEO of the South Korean company since 2016. | Health Technology |
NKMAX Co., Ltd.
NKMAX Co., Ltd. Pharmaceuticals: MajorHealth Technology NKMAX Co., Ltd. engages in the manufacture and sale of pharmaceutical products. It operates through the following business divisions: Immunity Cell Cure, Immunodiagnosis Kit, Health Functional Foods, and Bio Research. The company was founded on January 14, 2002 and is headquartered in Seongnam-si, South Korea. | Health Technology |
coAsia Biotech Corp.
coAsia Biotech Corp. BiotechnologyHealth Technology Part of NKMAX Co., Ltd. (South Korea), coAsia Biotech Corp. manufactures biological products. Sang-Woo Park has been the CEO of the Thai company since 2016. coAsia Biotech was acquired by NKMAX Co., Ltd. (South Korea) on February 28, 2018 for $0.10 million. | Health Technology |
| Nkmax H&D Co. Ltd. | |
| Atgen Japan | |
NKGen Biotech, Inc.
NKGen Biotech, Inc. BiotechnologyHealth Technology NKGen Biotech, Inc. is a biotechnology company which engages in harnessing the immune system through natural killer cell therapies. It develops a proprietary stabilizing peptide, monoclonal antibodies, and recombinant proteins for research use. The company was founded in 2002 and is headquartered in Santa Ana, CA. | Health Technology |
| Nkmax Japan, Inc. |
